Success Metrics

Clinical Success Rate
61.5%

Based on 8 completed trials

Completion Rate
62%(8/13)
Active Trials
1(7%)
Results Posted
150%(12 trials)
Terminated
5(33%)

Phase Distribution

Ph not_applicable
1
7%
Ph phase_1
9
60%
Ph phase_2
5
33%

Phase Distribution

9

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution15 total trials
Phase 1Safety & dosage
9(60.0%)
Phase 2Efficacy & side effects
5(33.3%)
N/ANon-phased studies
1(6.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

57.1%

8 of 14 finished

Non-Completion Rate

42.9%

6 ended early

Currently Active

1

trials recruiting

Total Trials

15

all time

Status Distribution
Active(1)
Completed(8)
Terminated(6)

Detailed Status

Completed8
Terminated5
Recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
15
Active
1
Success Rate
61.5%
Most Advanced
Phase 2

Trials by Phase

Phase 19 (60.0%)
Phase 25 (33.3%)
N/A1 (6.7%)

Trials by Status

completed853%
recruiting17%
terminated533%
withdrawn17%

Recent Activity

1 active trials
Showing 5 of 15
recruitingphase_2

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

NCT01042379
completednot_applicable

A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma

NCT02975700
terminatedphase_1

PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors

NCT02584647
completedphase_1

Safety Study of PLX108-01 in Patients With Solid Tumors

NCT01004861
completedphase_2

PLX3397 KIT in Acral aNd mucOsal Melanoma

NCT02071940
View all 15 trials

Clinical Trials (15)

Showing 15 of 15 trials
NCT01042379Phase 2

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Recruiting
NCT02975700Not Applicable

A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma

Completed
NCT02584647Phase 1

PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors

Terminated
NCT01004861Phase 1

Safety Study of PLX108-01 in Patients With Solid Tumors

Completed
NCT02071940Phase 2

PLX3397 KIT in Acral aNd mucOsal Melanoma

Completed
NCT01596751Phase 1

Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer

Completed
NCT01525602Phase 1

Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors

Completed
NCT01217229Phase 2

Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma

Completed
NCT01790503Phase 1

A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma

Completed
NCT01826448Phase 1

A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma

Terminated
NCT02452424Phase 1

A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors

Terminated
NCT01499043Phase 2

Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC)

Terminated
NCT01349036Phase 2

A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma

Terminated
NCT01349049Phase 1

Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Completed
NCT01090570Phase 1

Safety, Pharmacokinetic (PK), Pharmcodynamic (PD), and Drug-Drug Interaction of PLX3397 in Patients With Rheumatoid Arthritis Who Are Receiving Methotrexate

Withdrawn

All 15 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
15